SÚKL, is currently reviewing an application for insurance reimbursement of the weight-loss drug Wegovy specifically for obese pediatric patients aged 12 to 18, according to agency director Tomáš Boráň. While formal administrative proceedings are underway, regulators have not yet set a date for a final decision on whether public health insurance will cover the treatment.
Manufactured by Danish pharmaceutical company Novo Nordisk and introduced to the market in 2021, Wegovy is a next-generation weight-loss medication administered via a weekly injection. Compared to older alternatives, the drug has demonstrated better results in clinical settings. Currently, SÚKL is evaluating its reimbursement eligibility exclusively for adolescents between 12 and 18 years old suffering from obesity.
Strict Conditions for Insurance Coverage
If insurance coverage is approved, young patients will have to meet several mandatory criteria to qualify for state-funded support. State regulators and medical professionals emphasize that Wegovy is designed as a complementary treatment rather than a standalone solution. Patients must actively demonstrate that they are already attempting to lose weight through diet and exercise. If a patient fails to lose weight within 12 weeks of starting the medication, their entitlement to insurance reimbursement will be terminated.
At present, doctors can prescribe these medications to children, but families must cover the full cost out of pocket. Initial treatment weeks begin with a lower dose costing approximately 3,500 crowns per month, while the final maintenance variant costs over 5,000 crowns monthly. Jana Křenek Malíková, chair of the pediatric obesity section at the Czech Pediatric Society, noted that patients cannot simply use the drug for half a year and stop. Because obesity requires long-term management, securing insurance coverage would expand access to many more children who struggle with the condition.
Rising Childhood Obesity Rates Across the Czech Republic
Data from the international HBSC (Health Behaviour in School-aged Children) study shows a clear upward trend in Czech childhood obesity. The share of obese children rose from 4 percent in 2010 to 6.3 percent last year. Medical specialists highlight that anti-obesity medications are never the first choice; doctors prescribe them only after traditional lifestyle changes prove insufficient. Křenek Malíková explained that the treatment works largely by reducing appetite, making it easier for patients to manage smaller portions without constant cravings.
Did You Know? In pediatric medicine, obesity thresholds differ significantly from adult standards. For a 12-year-old boy standing 165 centimeters tall, the medical threshold for obesity begins at an approximate weight of 66 kilograms, as weight boundaries for children depend strictly on age and gender.
The data also reveals a strong correlation between childhood obesity and socioeconomic status. While only 4 percent of children in wealthier households suffer from obesity, the rate climbs to 9 percent—nearly one in ten—in poorer families. For these lower-income households, public reimbursement of the medication could prove financially decisive.
While the financial burden of out-of-pocket treatments currently limits access primarily to wealthier families, strict performance and behavioral criteria ensure that medication remains tied to active lifestyle efforts rather than replacing foundational health habits.
Potential Next Steps for Regulators and Families
As the administrative review continues, the timeline for a final ruling remains open. SÚKL officials have stated that it is not yet possible to predict when the formal decision will be issued. If the agency approves reimbursement, families of eligible adolescents could see state support alter the financial accessibility of long-term obesity treatment. Conversely, if the application is rejected, patients will continue to bear the full monthly cost of the weekly injections.
Questions about Wegovy reimbursement for pediatric patients
What is Wegovy and who makes it?
Wegovy is a next-generation weight-loss medication administered once a week, manufactured by the Danish pharmaceutical company Novo Nordisk and introduced to the market in 2021.
Which patients are included in the current review?
The current SÚKL administrative proceeding evaluates insurance reimbursement exclusively for obese pediatric patients between the ages of 12 and 18.
What happens if a patient does not lose weight during the treatment?
If a patient fails to lose weight within the first 12 weeks of using the medication, their claim to insurance reimbursement from the health insurer will be canceled.
What impact might insurance coverage for Wegovy have on lower-income families battling adolescent obesity?
Worth a look